CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 296 enrolled
Drug / intervention
MN-001 BID +2 moredrug
Likely dose
MN-001 BID 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00295854
NCT00295854Phase 2Completed
CompareCT.gov

A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

MediciNova·interventional·Posted Feb 24, 2006·Updated Jan 19, 2012

In Brief

A Phase 2 clinical trial evaluating MN-001 BID, MN-001, and 1 other intervention for Interstitial Cystitis. Completed, enrolled 296 participants across 28 sites.

Detailed Summary

To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInterstitial Cystitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 24, 2006
Enrollment StartMay 1, 2005
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 20.4 years ago

Interventions

MN-001 BIDdrug

Eligible patients received 500 mg MN-001 bid

MN-001drug

Eligible patients received 500 mg MN-001 once daily (qd)

Placebodrug

Eligible patients received placebo